Drs Lempert and Kushner1 question a number of decisions made in designing our randomized trial of patching vs atropine in children aged 3 to younger than 7 years with moderate amblyopia. We have previously answered similar questions from Dr Lempert both in press and in private communication.2- 4 The design of any randomized clinical trial requires a number of decisions regarding which treatments to compare and which outcome measures to use. Those decisions are made in light of the specific questions being asked and current understanding of the disease.
Repka MX, Wallace DK, Beck RW, Kraker RT, Birch EE, Cotter SA, Donahue S, Everett DF, Hertle RW, Holmes JM, Quinn GE, Scheiman MM, Weakley DR, for the Pediatric Eye Disease Investigator Group. Contradictions in the Amblyopia Treatment Studies—Reply. Arch Ophthalmol. 2006;124(2):285-287. doi:10.1001/archopht.124.2.285-b